IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene IFNA2 Ensembl ENSG00000188379 Chromosome 9 Start 21374253 End 21375387
Description Interferon alpha-2 Precursor (Interferon alpha-A)(LeIF A) [Source:UniProtKB/Swiss-Prot;Acc:P01563]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 5423
     Entrez Gene : 3440
     UCSC : uc003zpb.2
     GeneCards : 5423
     RefSeq : NM_000605
     CCDS : CCDS6506.1
     Uniprot : P01563
     Interpro : P01563
     OMIM : 147562
     GeneTests : IFNA2
     CGAP : IFNA2
     PMID : 1385305

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1791_s_at  0.05  8.30e-1  8.80e-1  0.43  1.89e-1  2.77e-1
 HG_U133A  211338_at  -0.13  3.82e-1  4.37e-1  3.24  1.97e-64  5.76e-64
 HG_U133_Plus2  211338_at  -0.02  9.47e-1  9.62e-1  -0.02  9.36e-1  9.49e-1
 Agilent_HS_21.6K  16081  0.06  6.39e-2  1.72e-1  0.06  6.35e-2  1.48e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  211338_at  0.13  7.84e-1  9.80e-1  -0.13  7.33e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1791_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211338_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211338_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 16081    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
alpha-2a interferon recurrent rectal cancer METHODS AND MATERIALS: In this Phase I pilot study, patients with locally advanced, unresectable, or recurrent rectal cancer with or without distant metastases received external beam pelvic radiotherapy over 5 to 6 weeks combined with escalating doses of 9069300 Human
alpha-2a interferon kasabach-merritt syndrome Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. 9121401 Human
alpha-2a interferon hemangioendothelioma Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. 9121401 Human
alpha-2a interferon essential thrombocythemia Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. 7864024 Human
alpha-2a interferon polycythemia vera Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. 7864024 Human
alpha-2a interferon mediastinal tumors Epithelioid hemangioendothelioma and other vascular mediastinal tumors: a role for alpha-2a interferon? 12902133 Human
alpha-2a interferon epithelioid hemangioendothelioma Epithelioid hemangioendothelioma and other vascular mediastinal tumors: a role for alpha-2a interferon? 12902133 Human
alpha-2a interferon chronic myeloproliferative disorders Twenty-one patients with chronic myeloproliferative disorders, eleven with polycythemia vera (PV) and ten with essential thrombocythemia (ET), were treated with small doses of alpha-2a interferon (IFN). 2055565 Human
ifnalpha2a tumors These data indicate that the tumor-homing peptide (NGR) can enhance the therapeutic efficacy of IFN-alpha2a against tumors. 17354103 Human
ifnalpha2a tumor These data indicate that the tumor-homing peptide (NGR) can enhance the therapeutic efficacy of IFN-alpha2a against tumors. 17354103 Human
cytokine b-cell chronic lymphocytic leukemia Alpha 2-interferon in B-cell chronic lymphocytic leukemia: clinical response, serum cytokine levels, and immunophenotype modulation. 7680399 Human
cytokine non-melanoma skin cancers Interferon-alpha (IFN-alpha) is a cytokine that is effective in the treatment of a variety of cancers, including non-melanoma skin cancers. 7705922 NA
cytokine cervical intraepithelial neoplasia The expression of genes coding for inflammatory cytokine interleukin-1-alpha (IL-1 alpha), IL-6, interferon-gamma and tumor necrosis factor-alpha from 15 normal cervix, 11 cervical intraepithelial neoplasia and 13 cervical cancer tissues was investigated. 7575522 Human
cytokine stage iv colorectal cancer A total of 29 patients with stage IV colorectal cancer were entered into a phase II trial of bolus interleukin-2 (IL-2) and interferon-alpha (IFN alpha) (3 x 10(6) U/m2 of each cytokine given i.v. q8h x 15 doses and repeated in 2 weeks). 8680653 NA
cytokine tumor The tumorigenicity of transplantable tumor cells in mice is reduced by transduction with cytokine genes, including IFN-alpha and interleukin (IL) 12. 9865738 Mouse
ifna glioblastomas Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, 1501894 Human
ifna malignant gliomas Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, 1501894 Human
ifna retinoblastoma Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, 1501894 Human
ifna brain tumors Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, 1501894 Human
ifna anaplastic astrocytomas Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, 1501894 Human
ifna nsclc To define the location and extent of deletions of 9p in NSCLC and MM, Southern blot analyses on six NSCLC and five MM cell lines using molecular probes to 9p loci (IFNA, IFNB1, D9S3, and D9S19) were performed, and DNA dosage was determined by densitometry 7688555 Human
ifna adenocarcinoma of the esophagus Since esophageal cancer shares characteristics with some of the above tumor types, we performed a detailed examination of 60 patients with squamous cell carcinoma or adenocarcinoma of the esophagus for LOH at loci D9S162, IFNA, D9S171, D9S126, D9S104, D9S 7954453 Human
ifna esophageal squamous-cell carcinoma By the microsatellite assay, two types of genetic alterations, loss of heterozygosity (LOH) and replication error (RER), were examined using 7 dinucleotide repeat markers [D3S1317 (3p26); CI3-1169 (3p25); CI3-946 (3p25); D3S1255 (3p24.2-25); CI3-771 (3p21 7850805 Human
ifna adenomas In order to elucidate the significance of the adenoma-carcinoma sequence in gastric carcinogenesis from a genetic point of view, we examined microsatellite alterations (replication error and loss of heterozygosity) on chromosomes 2p (D2S123), 3p (D3S1317) 7728762 Human
ifna nasopharyngeal carcinoma Nasopharyngeal carcinoma, which is very frequent in southern China, has in previous investigations been found to be associated with a number of risk factors, including a disease susceptibility gene linked to the HLA-region, p53 alleles and deletions of th 9111194 Human
ifna metastatic bladder cancers DESIGN: The authors examined the pattern of allelic loss with polymorphic microsatellite markers on chromosome 9p21 (D9S161, D9S171, IFNA), regions of putative tumor suppressor gene p16, and on chromosome 17p13 (TP53), the p53 locus, in matched primary an 11520271 Human
ifna metastatic cancer The frequency of allelic loss in matched metastatic cancer was 100% with D9S161, 62% with D9S171, 71% with IFNA, and 80% with TP53. 11520271 Human
ifna recurrent pituitary tumours In contrast, however, the metastatic lesion showed a loss-to-retention pattern at two distinct loci (IFNA and D22S156) compared to the primary and recurrent pituitary tumours. 11678840 Human
ifna ampullary carcinoma Sixty-two point five percent (5/8) of ampullary carcinoma cases showed loss of heterozygosity at one or more of the loci, frequent site of loss being D9S942 (42.9%) and the next most frequent being IFNA (37.5%) and D9S171 (37.5%). 11780432 Human
ifna benign melanocytic nevi We have analyzed 54 benign melanocytic nevi and 6 DMN for loss of heterozygosity (LOH) at microsatellite markers D9S171, IFNA, D9S270, D9S265. 12079204 Human
ifna small-cell carcinoma We examined five polymorphic microsatellite markers located on chromosome 3p25-26 (D3S3050), chromosome 9p21 (IFNA and D9S171), chromosome 9q32-33 (D9S177), and chromosome 17p13 (TP53) in 20 patients with small-cell carcinoma of the urinary bladder and co 15855652 Human
ifna urothelial carcinoma We examined five polymorphic microsatellite markers located on chromosome 3p25-26 (D3S3050), chromosome 9p21 (IFNA and D9S171), chromosome 9q32-33 (D9S177), and chromosome 17p13 (TP53) in 20 patients with small-cell carcinoma of the urinary bladder and co 15855652 Human
interferon alpha-2 metastatic renal cell cancer Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. 8804488 Human
interferon alpha-2 squamous cell carcinoma of the cervix Recent publications report on a synergistic effect of combination therapy using 13-cis-retinoic acid and interferon alpha-2 a in the treatment of squamous cell carcinoma of the cervix. 9036064 Human
alpha-2a interferon papillomatosis [Antibodies to alpha-2A interferon in children with juvenile respiratory papillomatosis] Follow-up of 36 JRP children and 12 controls (as shown by solid-phase enzyme immunoassay) has revealed that antibodies to IFN-alpha 2a with titers 1:20 to 1:1280 were 7502448 Human
ifn-alpha-2a neuroendocrine tumors METHODS. To verify the clinical activity of IFN, 49 evaluable patients with advanced stage low- and intermediate-grade neuroendocrine tumors were treated with recombinant IFN-alpha-2a at a daily dose of 6 x 10(6) IU intramuscularly for 8 weeks, and 3 time 7693327 Human
ifn-alpha-2a carcinoid syndrome CONCLUSIONS. The use of recombinant IFN-alpha-2a at these doses is well-tolerated and effective in controlling carcinoid syndrome (complete remission plus partial remission, 64%), although it has limited activity on tumor growth inhibition. 7693327 Human
ifn-alpha-2a hairy cell leukemia To explore the relationship between anti-interferon-alpha (anti-IFN-alpha) antibodies and loss of clinical responsiveness to IFN-alpha treatment, we examined sera from 59 patients with hairy cell leukemia who responded to therapy with recombinant IFN-alph 2070058 Human
ifn-alpha-2a kaposi's sarcoma Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. 2088534 Human
ifn alpha 2a chronic myeloid leukaemia (cml) Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden 8759890 Human
ifn alpha 2a hairy cell leukaemia Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden 8759890 Human
ifn alpha 2a solid tumours Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden 8759890 Human
ifn alpha 2a cml This data shows that a significant proportion of Ph+ CML patients receiving treatment with IFN alpha 2a can develop neutralizing antibodies and that these antibodies are associated with a loss of IFN alpha 2a efficacy. 8759890 Human
ifnalpha2a diffuse malignant mesothelioma (dmm) PURPOSE: To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM). 8622036 Human
ifnalpha2a refractory cancer PATIENTS AND METHODS: Thirty-three children with refractory cancer (stratified by age, < or = 12 and > 12 years) were treated with ATRA 3 consecutive days per week and IFN-alpha2a 3 x 10(6) U/m2 5 consecutive days per week, both repeated weekly. 9363862 Human
ifnalpha2a stage ii melanoma Using the trial demonstrating that interferonalpha-2a (IFNalpha-2a) is efficacious as adjuvant therapy in stage II melanoma, we evaluate its outcomes and economic consequences. 11239759 Human
ifnalpha2a stage ii melanoma Cost-effectiveness of IFNalpha-2a in stage II melanoma compares favourably with estimates for widely used therapies in the oncological field. 11239759 Human
ifnalpha2a liver cancer CONCLUSION: IFN-alpha2a enhanced the antitumor effect of capecitabine on HCC in nude mice, which might be ascribed to the up-regulation of TP expression in liver cancer tissues by IFN-alpha2a. 15071737 Mouse
ifnalpha2a tumor The cleavage pattern of rRNA induced by ECyd was similar and the cleavage sites were identical to those cleaved by RNase L. Additionaly, apoptosis induced by ECyd was elevated following the protein expression of RNase L in the tumor cells when treated wit 17150838 Human
ifnalpha2a head and neck cancer BACKGROUND: We have previously conducted phase II trials with a combination of 13-cis-retinoic acid (13-cRA), interferon-alpha2a (IFN-alpha2a), and alpha-tocopherol (alpha-TF) in patients with advanced oral premalignant lesions and locally advanced head a 17163463 Human
ifnalpha2a metastatic renal cell carcinoma [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta] BACKGROUND: The combination of interferon-alpha2a (IFN-alpha2a) and interleukin-2 (IL-2) induces objective responses in patients with metasta 17356836 Human
ifnalpha2a metastatic renal cell carcinoma (mrcc) [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta] BACKGROUND: The combination of interferon-alpha2a (IFN-alpha2a) and interleukin-2 (IL-2) induces objective responses in patients with metasta 17356836 Human
ifnalpha2a capillary hemangioma PURPOSE: To report the use of a combination of low-dose cyclophosphamide and interferon alfa 2a (IFNalpha2a) for the treatment of orbital juvenile capillary hemangioma. 17337066 Human
ifnalpha2a advanced colorectal cancer EXPERIMENTAL DESIGN: We studied 188 patients enrolled on protocol E2290, a five-arm trial comparing 5-FU, 5-FU in combination with N-phosphonoacetyl-l-aspartic acid, oral leucovorin, i.v. leucovorin, or IFNalpha-2a in patients with advanced colorectal can 17947473 Human
ifnalpha2a renal cell cancer Individual sensitivity of blood neutrophils to IFN-alpha2a was studied in vitro in patients with renal cell cancer before and after the first course of reaferon therapy. 18256759 Human
ifn-alpha-2a melanoma Thirty-three melanoma patients were prospectively investigated during adjuvant treatment with IFN-alpha-2a/2b (3 x 3 Mio units/wk). 17414324 Human
ifn-alpha-2a brain metastases METHODS: Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 microg. 18615619 Human
ifn-alpha-2a stage iv melanoma METHODS: Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 microg. 18615619 Human
ifn alpha 2a chronic myeloid leukaemia Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden 8759890 Human
ifnalpha2a diffuse malignant mesothelioma PURPOSE: To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM). 8622036 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.